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ヒトにおける尿中 5-アミノレブリン酸と
ニコチンアミド異化代謝産物排泄量との関係
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Relationship between Urinary Excretion Amounts of 5-Aminolevulinic Acid and 
Urinary Nicotinamide Catabolites in Humans
MORITA Nobuya and SHIBATA Katsumi
Summary :  5-Aminolevulinic acid （5-ALA） is used as a chemotherapeutic agent, and 5-ALA is 
a direct precursor of heme. Some B-group vitamins are required for the synthesis of 5-ALA from 
amino acids. 5-ALA is produced by the enzyme 5-ALA synthase, a vitamin B6-dependent enzyme 
in mitochondria, from glycine and succinyl-CoA. Succinyl-CoA is mainly synthesized from 
2-oxoglutaric acid + CoA by the enzyme 2-oxoglutaric acid dehydrogenase, which needs B-group 
vitamins such as thiamine diphosphate, FAD, and NAD+ as coenzymes. Succinyl-CoA is also 
synthesized from branched chain amino acids and so on. Suitable B-group vitamin administration 
might increase production of 5-ALA. Here, we investigated the relationships between vitamin 
nutritional status and 5-ALA production in humans. 5-ALA did not have a signiﬁcant relationship 
with the intake of vitamins B1, B2, B6, B12 and niacin. Furthermore, urinary excretion of 5-ALA did 
not correlate with urinary concentrations of vitamins B1 and B2. On the other hand, a strong, directly 
proportional relationship was observed between urinary excretion amounts of 5-ALA and sum of 
the nicotinamide catabolites such as N1-methylnicotinamide, N1-methyl-2-pyridone-5-carboxamide, 
and N1-methyl-4-pyridone-3-carboxamide （r2 = 0.494, P < 0.0001）. A significant correlation was 
also found between levels of urinary 5-ALA and 4-pyridoxic acid （a catabolite of vitamin B6） （r2 = 
0.220, P = 0.012）. Therefore, administration of niacin and vitamin B6 might help to increase 5-ALA 
production.
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要旨：5- アミノレブリン酸（5-ALA）は，化学療法剤として使用されている．5-ALA はヘ
ムの直接前駆体である．いくつかの B 群ビタミンは，5-ALA 合成に関与している．5-ALA
は，ミトコンドリアに存在するビタミン B6 酵素である 5-ALA 合成酵素によってグリシン
とスクシニル -CoA から合成される．スクシニル -CoA は，補酵素としてチアミン二リン酸，
FAD および NAD+ を必要とする 2- オキソグルタル酸デヒドロゲナーゼによって 2- オキソ
グルタル酸と CoA から主に合成される．さらに，スクシニル -CoA は分岐鎖アミノ酸など
からも合成される．適切な B 群ビタミンの補充は，5-ALA の産生を増加させる可能性があ
る．そこで我々は，ビタミン栄養状態と 5-ALA 産生との関係を調べた．今回のヒトを対象
とした調査実験では，尿中 5-ALA は，ビタミン B1，B2，B6，B12 およびナイアシンの摂取
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Introduction
Increased formation of 5-aminolevulinic acid （5-
ALA） in the body might help to prevent or delay 
some diseases; 5-ALA plus blue light illumination is 
used for the treatment of various premalignant and 
malignant lesions with some encouraging clinical 
outcomes （1,2）. The use of 5-ALA to improve 
glucose intolerance has been considered （3,4）. In 
addition, administration of 5-ALA to mice with 
sarcopenia improved physical performance （5）.
5-ALA is a key intermediate in heme synthesis, 
and is the ﬁrst compound in the porphyrin synthesis 
pathway （Fig. 1）.  5-ALA is produced by the 
enzyme 5-ALA synthase, a vitamin B6-dependent 
enzyme in mitochondria, （6） from glycine and 
succinyl-CoA. Succinyl-CoA is mainly synthesized 
from 2-oxoglutaric acid + CoA by the enzyme 
2-oxoglutaric acid dehydrogenase, which needs 
B-group vitamins such as thiamine diphosphate, FAD, 
and NAD+ as coenzymes. There are two pathways 
for the production of 2-oxoglutaric acid; the first is 
from isocitric acid from the TCA cycle, the second 
is from glutamic acid, glutamine, and some other 
amino acids （Fig. 1）. In addition, there is another 
origin of succinyl-CoA, from methylmalonyl-CoA via 
propionyl-CoA supplied through isoleucine, valine, 
and methionine （Fig. 1）.
Suitable B-group vitamin intake might increase 
5-ALA product ion.  So,  we invest igated the 
relationships between nutrient intake and 5-ALA 
production in humans. We report here that urinary 
excretion amounts of nicotinamide catabolites such 
as N1-methylnicotinamide （MNA）, N1-methyl-2-
pyridone-5-carboxamide （2-Py）, and N1-methyl-4-
pyridone-3-carboxamide （4-Py） were very highly 
correlated with urinary excretion of 5-ALA. Better 
niacin nutrition might make production of 5-ALA 
increase.
 
Materials and Methods
Chemicals
Thiamine hydrochloride （C12H17ClN4OS-HCl, 
molecular weight ［MW］ = 337.27）, riboflavin 
（C17H20N4O6, MW = 376.37）, cyanocobalamin 
（C63H88CoN14O14P, MW = 1355.40）, and nicotinamide 
（C6H6N2O, MW = 122.13） were purchased from 
Wako Pure Chemical Industries （Osaka Japan）, 
as was 4-pyridoxic acid （4-PIC; C8H9NO4, MW 
= 183.16） manufactured by ICN Pharmaceuticals 
（Costa Mesa, CA, USA）. 5-ALA hydrochloride 
（C5H5NO3-HCl, MW = 167.6） was purchased from 
Sigma （St. Louis, MO, USA）, and MNA chloride 
（C7H9N2O-HCl, MW = 159.61） was from Tokyo 
Chemical Industry （Tokyo, Japan）. 2-Py （C7H8N2O2, 
MW = 152.15） （7） and 4-Py （C7H8N2O2, MW = 
152.15） （8） were synthesized as described. All other 
chemicals were of the highest purity available from 
commercial sources.
Study design
The protocol conformed to the guidelines of 
the Declaration of Helsinki and was approved by 
the Ethics Committee of the University of Shiga 
Prefecture （Shiga, Japan） （approval number 343）. 
All participants provided written informed consent. 
Female Japanese students aged 20–21 years were 
recruited. Average body height, body weight, and 
量とは有意な関係を認めることはできなかった．さらに，尿中の 5-ALA 排泄量は，ビタミ
ン B1 および B2 の尿中排泄量と相関しなかった．一方，尿中 5-ALA 排泄量とニコチンアミ
ド異化代謝産物物である N1- メチルニコチンアミド，N1- メチル -2- ピリドン -5- カルボキ
サミドおよび N1- メチル -4- ピリドン -3- カルボキサミドの合計量排泄量との間には強い正
比例関係が認められた（r2 = 0.494, P < 0.0001）．さらに，尿中 5-ALA と 4- ピリドキシン酸（ビ
タミン B6 の異化代謝産物）量との間にも有意な相関が見られた（r2 = 0.220, P = 0.012）．し
たがって，ナイアシンやビタミン B6 補充は，ヘムの不足に起因するいくつかの疾患の予防
または遅延を助ける可能性がある．
キーワード：5- アミノレブリン酸，尿，人，ビタミン，アミノ酸
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body mass index were 156.8±5.0 （mean±SD, 
n = 28） cm, 49.8±5.1 kg, and 20.3±2.3 kg/m2, 
respectively. Individuals with a cold or influenza, 
or who had taken multivitamin supplements at least 
once during the previous month, were excluded. All 
28 participants were non-smokers, passed a standard 
medical examination, and completed the study.
The experimental  period was 4-days.  The 
experiment was done from Monday to Thursday. All 
food consumed during the 4-day period was recorded 
using a weighed food record method （9）. All the 
participants lived and consumed food freely during 
the experiment. A digital cooking scale （1 g unit; 
Tanita Inc. Tokyo, Japan）, a set of dietary record 
forms and a dietary record manual were distributed 
to the participants in advance （9）. Urine samples 
from the second urination on Thursday to the first 
urination on Friday were collected in amber bottles 
by the participants. All the urine samples from an 
individual were pooled before analysis and used to 
measure urine B-group vitamins and 5-ALA. After 
the urine samples were collected, the volumes of the 
samples were measured on Friday morning in our 
laboratory. Aliquots of the urine were stabilized to 
avoid destruction of B-group vitamins and 5-ALA. 
For analyses of urine thiamine, riboflavin, 4-PIC, 
nicotinamide, MNA, 2-Py, 4-Py, and 5-ALA, 1 
mL of 1 mol/L HCl was added to 9 mL urine. The 
treated urine samples were then stored at –80℃ until 
analysis. 
Measurement of B-group vitamins in urine
Thiamine.  Acidified frozen urine samples （about 
600 μL） were thawed and centrifuged at 10,000×g for 
10 min at 4℃. To each 500 μL supernatant sample was 
added 1% cyanogen bromide （100 μL） plus 5% （w/v） 
NaOH （100 μL）. After incubation at room temperature 
for 10 min, 1.5 mol/L HCl （80 μL） was added, and 
the mixture was centrifuged at 10,000×g for 10 min 
at 4℃. The resulting supernatant was passed through 
a 0.45-μm Hydrophilic Durapore™ filter （PVDF; 
Millipore, Bedford, MA, USA）. A 20 μL aliquot of 
Figure 1.  The biosynthesis of 5-aminolevulinic acid （5-ALA）, a precursor of heme, from succinyl-CoA and glycine. 5-ALA biosynthesis 
requires some B-group vitamins such as vitamin B1 （V.B1）, vitamin B2 （V.B2）, vitamin B6 （V.B6）, vitamin B12 （V.B12）, niacin, and 
pantothenic acid.
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ﬁltrate was injected directly into a high-performance 
liquid chromatography （HPLC） system to measure 
thiochrome concentration （10,11）.
Riboflavin and 4-PIC.  Acidified frozen urine 
samples （about 100 μL） were thawed and centrifuged 
at 10,000×g for 10 min at 4℃. The supernatants were 
decanted and passed through a 0.45-μm microfilter. 
Aliquots of filtrate （20 μL） were injected directly 
into a HPLC system to measure concentrations of 
riboﬂavin （12） and 4-PIC （13）.
Nicotinamide and its catabolites.  Acidiﬁed frozen 
urine samples （2.0 mL） were thawed and centrifuged 
at 10,000×g for 10 min at 4℃. Each supernatant （1.0 
mL） was added to 10 μL of 1.0 g/L isonicotinamide 
（used as an internal standard） and diethyl ether （5.0 
mL）, in the presence of K2CO3 （1.2 g）, to extract 
nicotinamide, 2-Py, and 4-Py from the water layer 
into the organic phase. This extraction procedure 
was repeated twice. The combined diethyl ether 
layer was dried at 40℃, and the dried materials were 
dissolved in 0.5 mL of water. The solution was passed 
through a 0.45-μm microﬁlter. Aliquots of ﬁltrate （20 
μL） were injected directly into a HPLC system to 
simultaneously measure nicotinamide, 2-Py, and 4-Py, 
as described （8）.
To measure MNA, urine samples （800 μL） were 
incubated with 0.1 mol/L acetophenone in ethanol 
（500 μL） and strong alkali （1.0 mL of 6 mol/L NaOH） 
in an ice-water bath. The reaction was performed in 
the presence of a large amount of isonicotinamide 
（200 μL of 1 mol/L）, which has been reported to 
interfere with the deamination of MNA under strongly 
alkaline conditions. Thus, after 10 min, 500 μL of 
formic acid was added and the mixture was kept for 
another 15 min in the ice-water bath. The mixture 
was then immersed in a boiling water bath for 5 min 
to yield 1-methyl-7-phenyl-1,5-dihydro-5-oxo-1,6-
naphthyridine. After cooling in an ice-water bath, the 
mixture was passed through a 0.45-μm microfilter, 
and the ﬁltrate （20 μL） injected directly into a HPLC 
system （14）.
Measurement of 5-ALA in urine
An acetylacetone reagent was prepared by mixing 
3 mL acetylacetone, 2 mL ethanol, and 15 mL 4 g/L 
NaCl. Formaldehyde was diluted 3.7-fold in water to 
10% and stored in the dark. 
Frozen acidified urine samples （100 μL） were 
thawed and centrifuged at 10,000×g for 10 min 
at 4℃ .  The supernatant was withdrawn, and 
fluorescence derivatization of 5-ALA performed 
essentially as described （15）. To each test tube with 
a sealed cap was added 20 μL urine supernatant, 
5 .0 mL acetylacetone reagent ,  and 0.45 mL 
10% formaldehyde, followed by vortexing for 
approximately 3 s. This mixture was immersed in a 
boiling water bath for 15 min and cooled in an ice-
water bath for at least 5 min to yield 2,6-diacetyl-
1,5-dimethyl-7-（2-carboxyethyl）-3H-pyrrolizine. 
The reaction mixture was passed through a 0.45-μ
m microﬁlter, and an aliquot of ﬁltrate （20 μL） was 
injected directly into a HPLC system, consisting of 
a Tosoh TSK-GEL ODS-80Ts column （250 mm×
4.6 mm I.D., particle size 5 μm） maintained at 40°С 
and eluted with methanol:acetic acid:water （90:4:106, 
v/v/v） at a flow rate of 0.6 mL/min. The excitation 
wavelength was 363 nm and the emission wavelength 
473 nm. In these conditions, the ﬂuorescent derivative 
of 5-ALA was eluted after 22.2 min.
Statistical analysis
Pearson coefficients were calculated to determine 
the correlation between urinary excretion of 5-ALA 
and energy intake, some nutrient intakes, and urinary 
excretion amounts of some vitamins. A p-value < 0.05 
was considered statistically significant. All analyses 
were performed using Graph Pad Prism version 5.0 
（Graph Pad Software, San Diego, CA, USA）.
RESULTS
Relationship between urinary excretion of 5-ALA 
and energy intake
Urinary 5-ALA excretion per day in the 28 healthy 
female students （n = 28） ranged from 2.07 μmol/d to 
9.86 μmol/d, with a median of 6.17 μmol/d. Figure 
2-A shows the relationship between urinary excretion 
of 5-ALA and energy intake. The average energy 
intake was 1434±370 （mean±SD） kcal/d. This 
relationship was not signiﬁcant. 
Relationship between urinary excretion of 5-ALA 
and major nutrient intakes 
The relationships between urinary excretion 
of 5-ALA and protein intake, fat intake, and 
carbohydrate intake are shown in Figs. 2-B, 2-C, and 
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2-D, respectively. These three relationships were not 
significant. The average intakes of protein, fat, and 
carbohydrate were 52.4±14.5 g/d, 43.6±20.0 g/d, 
and 210±73 g/d, respectively. 
Relationship between urinary excretion of 5-ALA 
and some vitamin intakes
Figure 3 shows the relationships between urinary 
excretion of 5-ALA and some B-group vitamins such 
as vitamin B1, vitamin B2, vitamin B6, niacin, and 
vitamin B12 which are involved in the biosynthesis 
of succinyl-CoA, a precursor of 5-ALA （see Fig. 1）. 
These relationships were not significant. However, 
a trend was observed between urinary excretion of 
5-ALA and niacin intake （Fig. 3-D）. The average 
intakes of vitamin B1, vitamin B2, vitamin B6, niacin, 
and vitamin B12 were 0.74±0.26 mg/d, 0.99±
0.45 mg/d, 0.96±0.34 mg/d, 21.4±1.84 mg niacin 
equivalent （NE）/d, and 2.9±1.8 μg/d, respectively. 
Relationship between urinary excretion of 5-ALA 
and urinary excretion amounts of some vitamins
 Figure 4 shows urinary amounts of vitamin B1, 
vitamin B2, 4-PIC （a catabolite of vitamin B6）, and 
vitamin B12. Urinary 5-ALA was not significantly 
related to urinary excretion of vitamin B1 （Fig. 
4-A）, vitamin B2 （Fig. 4-B） or vitamin B12 （Fig. 
4-D）. However, urinary 5-ALA showed a signiﬁcant 
association with urinary excretion of 4-PIC （Fig. 
4-C）. The average urinary excretion of vitamin B1, 
vitamin B2, 4-PIC, and vitamin B12 was 1.19±0.61 μ
mol/d, 0.55±0.47 μmol/d, 3.99±2.32 μmol/d, and 
31.9±1.9 nmol/d, respectively.
Relationship between urinary excretion of 5-ALA 
and urinary excretion amounts of nicotinamide 
catabolites
Figure 5 shows the relationship between urine 
5-ALA and nicotinamide and its metabolites. As has 
been reported previously （16）, urinary excretion of 
nicotinamide itself was below the limit of detection. A 
signiﬁcant correlation was observed between 5-ALA 
and each of the catabolites of nicotinamide. The 
strongest relationship was observed between SUM 
（i.e., MNA + 2-Py + 4-Py） and 5-ALA （Fig. 5-D）. 
The average urinary excretion of MNA, 2-Py, 4-Py, 
and the SUM （MNA + 2-Py + 4-Py） was 30.7±14.0 
μmol/d, 42.5±20.4 μmol/d, 5.6±2.7 μmol/d, and 
79.5±39.5μmol /d, respectively. 
DISCUSSION
The volunteers in the present experiment were 
within normal ranges physically and in nutrient 
intake. They had urinary 5-ALA levels similar to 
those previously reported （15）. Reference values 
of water-soluble vitamins for maintaining health 
have been reported to be 200–2000 nmol/d each 
for vitamins B1 and B2, 2–15 μmol/d for 4-PIC （a 
catabolite of vitamin B6）, and 50–300 μmol/d for 
the sum of nicotinamide catabolites MNA, 2-Py, and 
4-Py （17）. Of the 28 volunteers, three had higher 
than the reference values for vitamin B1, and seven, 
one, and four had lower than the reference values for 
vitamin B2, 4-PIC, and the sum of the nicotinamide 
catabolites, respectively. The elimination route of 
vitamin B12 is not via urine; therefore, we do not have 
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Figure 2.  Relationship between urinary excretion of 5-ALA 
and energy intake （A）, protein intake （B）, fat intake （C）, and 
carbohydrate intake （D）. 
Figure 3.  Relationship between urinary excretion of 5-ALA and 
vitamin B1 intake （A）, vitamin B2 intake （B）, vitamin B6 intake 
（C）, niacin intake （D）, and vitamin B12 intake （E）.
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a reference value for urinary excretion of vitamin 
B12 （18）. From these findings, we judged that the 
participants in this experiment were representative of 
young adult women.
We found that urinary 5-ALA levels were strongly 
correlated with urinary levels of nicotinamide 
catabolites such as MNA, 2-Py, and 4-Py, and 
weakly, but significantly, correlated with urinary 
4-PIC. Urinary 5-ALA did not correlate with urinary 
concentrations of vitamins B1 and B2. Greater urinary 
5-ALA excretion may indicate increased synthesis 
of 5-ALA, or reduced activity of 5-ALA dehydratase 
（18,19） which needs Zn2 + （20）. 
In toxicology, an increased 5-ALA level suggests 
lead （Pb） exposure because Pb inhibits 5-ALA 
dehydratase activity （21）. Exposure to Pb also 
inhibits the activity of NAD+ synthetase （22） which 
needs Mg2+ and K+ （23） and is an enzyme involved 
in the biosynthesis of NAD+ from tryptophan （23） 
that catalyzes the reaction nicotinic acid adenine 
dinucleotide + glutamine + ATP → NAD+ + glutamic 
acid + ADP + H3PO4. The free form of nicotinamide is 
formed only via NAD+ in the tryptophan-nicotinamide 
pathway. If the participants in our study had been 
exposed to Pb, it is probable that the increased 
urinary excretion of 5-ALA would be concomitant 
with decreased urinary excretion of nicotinamide 
metabolites. However, our data showed increased 
urinary excretion of both 5-ALA and nicotinamide 
and, further, a direct relationship was observed 
between them. Although we did not measure the blood 
Pb concentration or the relationship between urinary 
excretion of 5-ALA and Pb intake, we can conclude 
that the increased urinary excretion of 5-ALA was not 
due to the inhibition of 5-ALA dehydratase activity 
by Pb. Therefore, the present data showing increased 
urinary excretion of 5-ALA indicate a real elevation 
of 5-ALA synthesis from precursors such as glycine 
and succinyl-CoA. 5-ALA synthase is a pyridoxal 
phosphate-dependent enzyme （2）. The relationship 
between the urinary excretion of 4-PIC, a catabolite 
of vitamin B6, and the urinary excretion of 5-ALA 
was signiﬁcant.
As Fig. 1 shows, some B-group vitamins are 
involved in the synthesis of succinyl-CoA. Better 
nutritional status regarding B-group vitamins could 
increase the synthesis of succinyl-CoA. Urinary 
excretion of vitamins indicates surplus vitamin 
intake （17）, and higher urinary excretion of vitamins 
indicates better nutritional status of vitamins. Our 
data suggest that administration of some nutrients 
such as niacin and vitamin B6 （as well as some amino 
acids） may help to synthesize 5-ALA. As mentioned 
above, 5-ALA plus blue light illumination for the 
treatment of various premalignant and malignant 
lesions （1,2）, the use of 5-ALA for improvement 
of glucose intolerance （3,4）, and administration of 
5-ALA to improve sarcopenia （5） have been reported. 
Therefore, some physiological functions of niacin 
and vitamin B6 may actually arise through 5-ALA, 
a direct precursor of heme. Heme is a cofactor of 
proteins such as hemoglobin, cytochrome P450s, 
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Figure 4.  Relationship between urinary excretion of 5-ALA and 
urinary excretion of vitamin B1 （A）, vitamin B2 （B）, 4-pyridoxic 
acid ［4-PIC, a catabolite of vitamin B6］ （C）, and vitamin B12 （D）.
Figure 5.  Relationship between urinary excretion of 5-ALA and 
urinary excretion of N1-methylnicotinamide ［MNA］ （A）, N1-
methyl-2-pyridone-5-carboxamide ［2-Py］ （B）, N1-methyl-4-
pyridone-3-carboxamide ［4-Py］ （C）, and of the SUM ［i.e., MNA 
+ 2-Py + 4-Py］ （D）.
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other cytochromes （e.g. in the respiratory chain）, 
catalase, and oxygenases （see Fig. 1）. In particular, 
two oxygenases （tryptophan 2,3-dioxygenase （24）, 
indoleamine 2,3-dioxygenase （24）） are involved in 
the biosynthesis of nicotinamide from tryptophan. 
In the present experiment involving humans, a 
strong, directly proportional relationship was observed 
between the urinary excretion amounts of 5-ALA 
and nicotinamide catabolites. This result shows a 
direct relationship between the syntheses of 5-ALA 
from succinyl-CoA + glycine and nicotinamide from 
tryptophan.
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